It enhances tumor antigen release and potentially increases the effectiveness of ICIs that block inhibitory pathways, such as PD-1/PD-L1 and CTLA-4, and restores T-cell activity against tumor cells. The gene discussed is CTLA4; the disease is neoplasm.